RECURRENT OVARIAN CANCER
Clinical trials for RECURRENT OVARIAN CANCER explained in plain language.
Never miss a new study
Get alerted when new RECURRENT OVARIAN CANCER trials appear
Sign up with your email to follow new studies for RECURRENT OVARIAN CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for tough ovarian cancer
Disease control CompletedThis early-phase study tested whether adding a new drug called LDE225 to standard chemotherapy (paclitaxel) is safe for women with ovarian cancer that no longer responds to platinum-based treatments. Fifteen participants were monitored for side effects and to find the best dose. …
Matched conditions: RECURRENT OVARIAN CANCER
Phase: PHASE1 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Could a common cholesterol drug help fight ovarian cancer?
Disease control CompletedThis early-phase study tested whether adding simvastatin, a common cholesterol-lowering drug, to standard chemotherapy could slow cancer progression in women with recurrent platinum-sensitive ovarian cancer. 18 participants took simvastatin alongside carboplatin and liposomal dox…
Matched conditions: RECURRENT OVARIAN CANCER
Phase: EARLY_PHASE1 • Sponsor: Marc Goodman • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New drug combo shows promise for resistant ovarian cancer
Disease control CompletedThis study tested a new drug called relacorilant combined with chemotherapy (nab-paclitaxel) in 178 women with ovarian, fallopian tube, or peritoneal cancer that came back and no longer responds to platinum-based treatments. The goal was to see if the combination helps keep the c…
Matched conditions: RECURRENT OVARIAN CANCER
Phase: PHASE2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC